Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation

Kenji Shibuta, Masaki Mori, Katsuhiro Shimoda, Hiroshi Inoue, Prasenjit Mitra, Graham F. Barnard

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The CXCL12/CXCR4 system may be important in carcinoma. Expression of the α-chemokine SDF-lα (stromal cell derived factor-lα)/CXCL12 mRNA is reduced in many carcinomas, yet its tissue protein expression may guide metastasis. Here we first compare the mRNA and protein expression of CXCL12 and its receptor CXCR4 in human liver, hepatocellular carcinoma, and malignant cell lines, and then assess cell cycle variation in CXCR4 expression. CXCR4 mRNA was present in most normal human tissues and malignant cell lines; it was only marginally reduced in hepatomas, while CXCL12 was markedly reduced, P<0.0001. Immuno-histochemical staining of adjacent non-malignant liver showed regional CXCR4 cytoplasmic and cell-surface staining, limited to those hepatocytes around the central vein, a distribution resembling that of CXCL12. CXCL12 protein was not present in hepatocellular carcinoma cells in vivo, nor was cytoplasmic CXCR4 staining; nuclear CXCR4 protein expression in some malignant hepatocytes and CXCR4 staining of capillary endothelial cells around tumor cells were noted. In some malignant cell lines that had no CXCL12 on northern blots CXCL12 was weakly detectable by RT-PCR or protein staining in the cytoplasm of a few cells. With a view to future manipulation of CXCL12/CXCR4 expression and growth we noted that in HT-29 cells CXCR4 protein expression was less on confluent than on non-confluent cells and varied during the cell cycle. Higher expression was associated most closely with the percentage of cells in the S-phase and inversely with the percentage of cells in the G1-phase. Treatment of HT-29 cells with butyrate reduced CXCR4 cell surface expression and reduced the percentage of cells in S-phase. In summary, CXCL12 protein expression parallels its mRNA, being markedly reduced in malignant cell lines and hepatomas; in liver, the regional distributions of CXCL12 and cytoplasmic CXCR4 are similar; finally, in HT-29, CXCR4 expression correlates with the S-phase of the cell and is reduced during butyrate-induced differentiation.

Original languageEnglish
Pages (from-to)789-797
Number of pages9
JournalJapanese Journal of Cancer Research
Volume93
Issue number7
DOIs
Publication statusPublished - Jan 1 2002

Fingerprint

Hepatocellular Carcinoma
Cell Cycle
Liver
Staining and Labeling
S Phase
Cell Line
HT29 Cells
Messenger RNA
Proteins
Butyrates
Hepatocytes
In Vitro Techniques
CXCR4 Receptors
Carcinoma
G1 Phase
Stromal Cells
Nuclear Proteins
Chemokines
Northern Blotting
Veins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation. / Shibuta, Kenji; Mori, Masaki; Shimoda, Katsuhiro; Inoue, Hiroshi; Mitra, Prasenjit; Barnard, Graham F.

In: Japanese Journal of Cancer Research, Vol. 93, No. 7, 01.01.2002, p. 789-797.

Research output: Contribution to journalArticle

Shibuta, Kenji ; Mori, Masaki ; Shimoda, Katsuhiro ; Inoue, Hiroshi ; Mitra, Prasenjit ; Barnard, Graham F. / Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation. In: Japanese Journal of Cancer Research. 2002 ; Vol. 93, No. 7. pp. 789-797.
@article{1dc4675dd0204c428165140d5fbaa545,
title = "Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation",
abstract = "The CXCL12/CXCR4 system may be important in carcinoma. Expression of the α-chemokine SDF-lα (stromal cell derived factor-lα)/CXCL12 mRNA is reduced in many carcinomas, yet its tissue protein expression may guide metastasis. Here we first compare the mRNA and protein expression of CXCL12 and its receptor CXCR4 in human liver, hepatocellular carcinoma, and malignant cell lines, and then assess cell cycle variation in CXCR4 expression. CXCR4 mRNA was present in most normal human tissues and malignant cell lines; it was only marginally reduced in hepatomas, while CXCL12 was markedly reduced, P<0.0001. Immuno-histochemical staining of adjacent non-malignant liver showed regional CXCR4 cytoplasmic and cell-surface staining, limited to those hepatocytes around the central vein, a distribution resembling that of CXCL12. CXCL12 protein was not present in hepatocellular carcinoma cells in vivo, nor was cytoplasmic CXCR4 staining; nuclear CXCR4 protein expression in some malignant hepatocytes and CXCR4 staining of capillary endothelial cells around tumor cells were noted. In some malignant cell lines that had no CXCL12 on northern blots CXCL12 was weakly detectable by RT-PCR or protein staining in the cytoplasm of a few cells. With a view to future manipulation of CXCL12/CXCR4 expression and growth we noted that in HT-29 cells CXCR4 protein expression was less on confluent than on non-confluent cells and varied during the cell cycle. Higher expression was associated most closely with the percentage of cells in the S-phase and inversely with the percentage of cells in the G1-phase. Treatment of HT-29 cells with butyrate reduced CXCR4 cell surface expression and reduced the percentage of cells in S-phase. In summary, CXCL12 protein expression parallels its mRNA, being markedly reduced in malignant cell lines and hepatomas; in liver, the regional distributions of CXCL12 and cytoplasmic CXCR4 are similar; finally, in HT-29, CXCR4 expression correlates with the S-phase of the cell and is reduced during butyrate-induced differentiation.",
author = "Kenji Shibuta and Masaki Mori and Katsuhiro Shimoda and Hiroshi Inoue and Prasenjit Mitra and Barnard, {Graham F.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1111/j.1349-7006.2002.tb01321.x",
language = "English",
volume = "93",
pages = "789--797",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation

AU - Shibuta, Kenji

AU - Mori, Masaki

AU - Shimoda, Katsuhiro

AU - Inoue, Hiroshi

AU - Mitra, Prasenjit

AU - Barnard, Graham F.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The CXCL12/CXCR4 system may be important in carcinoma. Expression of the α-chemokine SDF-lα (stromal cell derived factor-lα)/CXCL12 mRNA is reduced in many carcinomas, yet its tissue protein expression may guide metastasis. Here we first compare the mRNA and protein expression of CXCL12 and its receptor CXCR4 in human liver, hepatocellular carcinoma, and malignant cell lines, and then assess cell cycle variation in CXCR4 expression. CXCR4 mRNA was present in most normal human tissues and malignant cell lines; it was only marginally reduced in hepatomas, while CXCL12 was markedly reduced, P<0.0001. Immuno-histochemical staining of adjacent non-malignant liver showed regional CXCR4 cytoplasmic and cell-surface staining, limited to those hepatocytes around the central vein, a distribution resembling that of CXCL12. CXCL12 protein was not present in hepatocellular carcinoma cells in vivo, nor was cytoplasmic CXCR4 staining; nuclear CXCR4 protein expression in some malignant hepatocytes and CXCR4 staining of capillary endothelial cells around tumor cells were noted. In some malignant cell lines that had no CXCL12 on northern blots CXCL12 was weakly detectable by RT-PCR or protein staining in the cytoplasm of a few cells. With a view to future manipulation of CXCL12/CXCR4 expression and growth we noted that in HT-29 cells CXCR4 protein expression was less on confluent than on non-confluent cells and varied during the cell cycle. Higher expression was associated most closely with the percentage of cells in the S-phase and inversely with the percentage of cells in the G1-phase. Treatment of HT-29 cells with butyrate reduced CXCR4 cell surface expression and reduced the percentage of cells in S-phase. In summary, CXCL12 protein expression parallels its mRNA, being markedly reduced in malignant cell lines and hepatomas; in liver, the regional distributions of CXCL12 and cytoplasmic CXCR4 are similar; finally, in HT-29, CXCR4 expression correlates with the S-phase of the cell and is reduced during butyrate-induced differentiation.

AB - The CXCL12/CXCR4 system may be important in carcinoma. Expression of the α-chemokine SDF-lα (stromal cell derived factor-lα)/CXCL12 mRNA is reduced in many carcinomas, yet its tissue protein expression may guide metastasis. Here we first compare the mRNA and protein expression of CXCL12 and its receptor CXCR4 in human liver, hepatocellular carcinoma, and malignant cell lines, and then assess cell cycle variation in CXCR4 expression. CXCR4 mRNA was present in most normal human tissues and malignant cell lines; it was only marginally reduced in hepatomas, while CXCL12 was markedly reduced, P<0.0001. Immuno-histochemical staining of adjacent non-malignant liver showed regional CXCR4 cytoplasmic and cell-surface staining, limited to those hepatocytes around the central vein, a distribution resembling that of CXCL12. CXCL12 protein was not present in hepatocellular carcinoma cells in vivo, nor was cytoplasmic CXCR4 staining; nuclear CXCR4 protein expression in some malignant hepatocytes and CXCR4 staining of capillary endothelial cells around tumor cells were noted. In some malignant cell lines that had no CXCL12 on northern blots CXCL12 was weakly detectable by RT-PCR or protein staining in the cytoplasm of a few cells. With a view to future manipulation of CXCL12/CXCR4 expression and growth we noted that in HT-29 cells CXCR4 protein expression was less on confluent than on non-confluent cells and varied during the cell cycle. Higher expression was associated most closely with the percentage of cells in the S-phase and inversely with the percentage of cells in the G1-phase. Treatment of HT-29 cells with butyrate reduced CXCR4 cell surface expression and reduced the percentage of cells in S-phase. In summary, CXCL12 protein expression parallels its mRNA, being markedly reduced in malignant cell lines and hepatomas; in liver, the regional distributions of CXCL12 and cytoplasmic CXCR4 are similar; finally, in HT-29, CXCR4 expression correlates with the S-phase of the cell and is reduced during butyrate-induced differentiation.

UR - http://www.scopus.com/inward/record.url?scp=0036051818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036051818&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2002.tb01321.x

DO - 10.1111/j.1349-7006.2002.tb01321.x

M3 - Article

C2 - 12149145

AN - SCOPUS:0036051818

VL - 93

SP - 789

EP - 797

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -